MEDVi vs Willow
$399/mo against $399/mo for tirzepatide. Which is worth it, and for whom.
Updated 2026-09-18
Both sell tirzepatide. MEDVi costs $399 a month and Willow costs $399. The desk reads it as follows.
MEDVi is tablet and injection choice. Willow is straightforward single-price plans. They are not aimed at the same person, and the cheaper one is not automatically the right answer — though on this board it usually is.
Advert against bill. MEDVi advertises $399 and bills $399; Willow advertises $399 and bills $399. Both gaps are the same size, so the advertised comparison happens to hold.
Side by side
| MEDVi | Willow | |
|---|---|---|
| Advertised | $399 | $399 |
| Billed | $399 | $399 |
| Gap | none | none |
| Per year, billed | $4,788 | $4,788 |
Prices verified 2026-09-18. "True monthly cost" is what you are billed in month two, once any introductory rate has lapsed and any membership has renewed.
The split
1 differences on the record. The others match.
| MEDVi | Willow | |
|---|---|---|
| Offers an oral or sublingual option | Yes | No |
What each puts on the record: MEDVi
Where it wins: Injection pricing is consistent between the first month and renewals. Watch for: You have to complete intake before seeing tablet pricing. Injection pricing is published at $399.
What each puts on the record: Willow
Where it wins: A single price with no membership arithmetic. Watch for: There is little published detail on how dose changes are handled. Ask before committing.
In each one’s favour
MEDVi.
- Injection pricing is consistent between the first month and renewals.
- Tablet option for people who will not inject.
Willow.
- A single price with no membership arithmetic.
Willow scores higher overall at 2.9 out of 5. The weights are published on how we rate, and so is the note about which of these is our paid featured partner.
The desk’s call
The board says MEDVi. What the board cannot say is whether the advertised figures you were shown elsewhere match these — check the gap row, because a listing that advertises low and bills high will beat an honest one in any comparison built on advertised prices.
The verdict
On the board, MEDVi at $399 a month is the more defensible choice on arithmetic alone. Willow earns its premium only if you will actually use what it does differently. Read the full reviews before deciding: MEDVi and Willow.
How they sit against everyone else
| Programme | Advertised | Billed | Gap | Vs board floor |
|---|---|---|---|---|
| Coreage Rx | $149 | $199 | +$50 | +$74/mo |
| Trimi | $125 | $125 | none | — |
| Ozari Health | $125 | $125 | none | — |
| Fifty 410 | $133 | $133 | none | +$8/mo |
More from the desk
- MEDVi tirzepatide review
Advertised at $399 and billed at $399 — no gap. Position 14 of 18 on our board.
- Willow tirzepatide review
Advertised at $399 and billed at $399 — no gap. Position 15 of 18 on our board.
- How to spot a bad seller
The FDA sent more than 55 warning letters to online GLP-1 sellers in one day. Here is how to tell a licensed programme from the rest.
- The twelve-month cost
Month one is the cheapest month you will have. Here is the full-year arithmetic, including the costs nobody puts in the advert.
- Cheapest right now
Every programme sorted on what it bills, not what it advertises. Floor: $199/mo tirzepatide, $149/mo semaglutide.
Coreage Rx pays us a commission on sign-ups through our links. It does not affect our scores or rankings. How we rate · Disclosure